Website
News25/Ratings1
Price$1.26-0.35 (-21.43%)
2026-01-202026-04-23
News · 26 weeks44+40%
2025-10-262026-04-19
Mix1690d
- SEC Filings9(56%)
- Insider2(13%)
- Other2(13%)
- Earnings2(13%)
- Analyst1(6%)
Latest news
25 items- SECSEC Form DEFA14A filed by InspireMD Inc.DEFA14A - InspireMD, Inc. (0001433607) (Filer)
- SECSEC Form DEFA14A filed by InspireMD Inc.DEFA14A - InspireMD, Inc. (0001433607) (Filer)
- SECSEC Form DEF 14A filed by InspireMD Inc.DEF 14A - InspireMD, Inc. (0001433607) (Filer)
- SECSEC Form PRE 14A filed by InspireMD Inc.PRE 14A - InspireMD, Inc. (0001433607) (Filer)
- SECInspireMD Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - InspireMD, Inc. (0001433607) (Filer)
- SECSEC Form 424B5 filed by InspireMD Inc.424B5 - InspireMD, Inc. (0001433607) (Filer)
- PRInspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare ConferenceMIAMI, March 31, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th at 12:45 pm Eastern Time (ET). A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com. About InspireMD, Inc.InspireMD seeks to utilize its proprietary MicroNet™ mesh technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable, stroke-free lon
- SECSEC Form 10-K filed by InspireMD Inc.10-K - InspireMD, Inc. (0001433607) (Filer)
- SECSEC Form 8-K filed by InspireMD Inc.8-K - InspireMD, Inc. (0001433607) (Filer)
- PRInspireMD Reports Fourth Quarter and Full Year 2025 Financial ResultsMIAMI, March 18, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced financial and operating results for the fourth quarter and year ended December 31, 2025. Recent Business Highlights: Generated revenue of $3.1 million in the fourth quarter of 2025, up 62% year-over-year.Sustained strong commercial traction in the U.S. with the launch of CGuard Prime and continued growth in international demand for CGuard.Supported over 500 cumulative carotid procedures utilizing CGuard Prime across leading hospitals and integrated delivery networks since launch.Co
- PRInspireMD to Announce Fourth Quarter and Full Year 2025 Financial ResultsMIAMI, March 09, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced that it will release its fourth quarter and full year 2025 financial results on Wednesday, March 18, 2026. In conjunction with the release, InspireMD will host a conference call and webcast at 8:30 a.m. Eastern Time to discuss its financial results and recent highlights. A live audio webcast and an archive of the recording will be available through the Investors page of InspireMD's corporate website at https://investors.inspiremd.com. Interested participants are encouraged to register more than 15 minutes before the star
- SECInspireMD Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits8-K - InspireMD, Inc. (0001433607) (Filer)
- INSIDERAmendment: Director Stuka Paul bought $4,905 worth of shares (2,710 units at $1.81), increasing direct ownership by 0.70% to 391,628 units (SEC Form 4)4/A - InspireMD, Inc. (0001433607) (Issuer)
- SECSEC Form SCHEDULE 13G filed by InspireMD Inc.SCHEDULE 13G - InspireMD, Inc. (0001433607) (Subject)
- INSIDERChief Commercial Officer Gleason Shane Thomas sold $99,331 worth of shares (61,194 units at $1.62), decreasing direct ownership by 5% to 1,139,177 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- ANALYSTMaxim Group initiated coverage on InspireMD with a new price targetMaxim Group initiated coverage of InspireMD with a rating of Buy and set a new price target of $6.00
- PRInspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the Compensation Committee of InspireMD's Board of Directors approved inducement grants to one (1) new non-executive employee in the aggregate amount of 36,118 shares of restricted stock (the "Inducement Grants") outside of InspireMD's 2021 Equity Incentive Plan, with a grant date as of January 14, 2026, as an inducement material to the non-executive employees entering into employment with InspireMD, in accordance with Nasdaq Listing Rule 5635(c)(4). The Inducement Grants were granted u
- INSIDERDirector Ward Scott R. was granted 88,053 shares, increasing direct ownership by 147% to 147,846 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERChief Operating Officer Tommasoli Andrea was granted 226,695 shares, increasing direct ownership by 31% to 954,389 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERDirector Stuka Paul was granted 132,076 shares, increasing direct ownership by 34% to 523,704 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERCEO and President Slosman Marvin was granted 1,114,792 units of Restricted Stock Units, increasing direct ownership by 46% to 3,535,658 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERDirector Roubin Gary S was granted 88,053 shares, increasing direct ownership by 13% to 744,478 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERChief Financial Officer Lawless Michael A was granted 226,695 shares, increasing direct ownership by 49% to 691,695 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERChief Commercial Officer Gleason Shane Thomas was granted 453,390 shares, increasing direct ownership by 61% to 1,200,371 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)
- INSIDERDirector Dearen Danny L. was granted 44,030 shares, increasing direct ownership by 76% to 102,047 units (SEC Form 4)4 - InspireMD, Inc. (0001433607) (Issuer)